array:24 [ "pii" => "S2253808922001094" "issn" => "22538089" "doi" => "10.1016/j.remnie.2022.11.003" "estado" => "S300" "fechaPublicacion" => "2023-03-01" "aid" => "1405" "copyright" => "Sociedad Española de Medicina Nuclear e Imagen Molecular" "copyrightAnyo" => "2022" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Rev Esp Med Nucl Imagen Mol. 2023;42:77-82" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S2253654X22001378" "issn" => "2253654X" "doi" => "10.1016/j.remn.2022.09.005" "estado" => "S300" "fechaPublicacion" => "2023-03-01" "aid" => "1405" "copyright" => "Sociedad Española de Medicina Nuclear e Imagen Molecular" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Rev Esp Med Nucl Imagen Mol. 2023;42:77-82" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">ORIGINAL</span>" "titulo" => "PET/TC en endocrinología nuclear. Resultados de la encuesta difundida por las distintas redes sociales de la SEMNIM en España" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "77" "paginaFinal" => "82" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "PET/CT in nuclear endocrinology: Results of the survey diffused through different social networks of the SEMNIM in Spain" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figura 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1902 "Ancho" => 2091 "Tamanyo" => 206063 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Uso de la <span class="elsevierStyleSup">18</span>F-FDG PET/TC en el diagnóstico y/o seguimiento del CDT. A. Número de centros que utilizan la técnica respecto al total (en tanto por ciento). B. Relación del número de centros que utilizan la técnica en la indicación descrita.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M. Negre Busó, M. Estorch Cabrera, M. Mitjavila Casanovas" "autores" => array:4 [ 0 => array:2 [ "nombre" => "M." "apellidos" => "Negre Busó" ] 1 => array:2 [ "nombre" => "M." "apellidos" => "Estorch Cabrera" ] 2 => array:2 [ "nombre" => "M." "apellidos" => "Mitjavila Casanovas" ] 3 => array:1 [ "colaborador" => "en nombre del Grupo de Trabajo de Endocrinología de la SEMNIM" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2253808922001094" "doi" => "10.1016/j.remnie.2022.11.003" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253808922001094?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253654X22001378?idApp=UINPBA00004N" "url" => "/2253654X/0000004200000002/v2_202303161341/S2253654X22001378/v2_202303161341/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2253808922001070" "issn" => "22538089" "doi" => "10.1016/j.remnie.2022.11.001" "estado" => "S300" "fechaPublicacion" => "2023-03-01" "aid" => "1402" "copyright" => "Sociedad Española de Medicina Nuclear e Imagen Molecular" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Rev Esp Med Nucl Imagen Mol. 2023;42:83-92" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "Progress and current utility of radiomics in PET/CT study of non-metastatic breast cancer: A systematic review" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "83" "paginaFinal" => "92" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Progreso y utilidad actual de la radiómica dentro del estudio PET/TC en cáncer de mama no metastásico: una revisión sistemática" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2515 "Ancho" => 1341 "Tamanyo" => 253709 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Search and selection process of articles included in the review.</p> <p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">241 articles identified PubMed (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>72), WOS (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>174), Scopus (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>108).</p> <p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">76 duplicated articles 55 articles outside the field of oncology 109 non eligible articles 36 articles of presentations or communications in congresses 56 articles fulfilled inclusion criteria 38 articles fulfilled exclusion criteria 18 articles included in the review.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "P.M. Cárcamo Ibarra, U.A. López González, A. Esteban Hurtado, M.A. Navas de la Cruz, L. Asensio Valero, S. Diez Domingo" "autores" => array:6 [ 0 => array:2 [ "nombre" => "P.M." "apellidos" => "Cárcamo Ibarra" ] 1 => array:2 [ "nombre" => "U.A." "apellidos" => "López González" ] 2 => array:2 [ "nombre" => "A." "apellidos" => "Esteban Hurtado" ] 3 => array:2 [ "nombre" => "M.A." "apellidos" => "Navas de la Cruz" ] 4 => array:2 [ "nombre" => "L." "apellidos" => "Asensio Valero" ] 5 => array:2 [ "nombre" => "S." "apellidos" => "Diez Domingo" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S2253654X22001214" "doi" => "10.1016/j.remn.2022.08.005" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253654X22001214?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253808922001070?idApp=UINPBA00004N" "url" => "/22538089/0000004200000002/v2_202311010503/S2253808922001070/v2_202311010503/en/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S2253808921001737" "issn" => "22538089" "doi" => "10.1016/j.remnie.2021.12.005" "estado" => "S300" "fechaPublicacion" => "2023-03-01" "aid" => "1351" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Rev Esp Med Nucl Imagen Mol. 2023;42:71-6" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "<span class="elsevierStyleSup">177</span>Lu-PSMA-617 RLT in mCRPC: A single center experience, the earlier could be the better" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "71" "paginaFinal" => "76" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "<span class="elsevierStyleSup">177</span>Lu-PSMA-617 RLT en mCRPC: Una experiencia de un solo centro, cuanto antes podría ser mejor" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1494 "Ancho" => 1674 "Tamanyo" => 116660 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0010" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Comparison of OS between patients receiving <span class="elsevierStyleSup">177</span>Lu-PSMA-617-RLT at or below third line and patients receiving higher than third line. When the two groups were compared, it was found that the OS of the patients who received the treatment at the third line or earlier was higher.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Ozlem Nuray Sever, Umut Elboga, Ertan Sahin, Yusuf Burak Cayirli, Havva Yesil Cinkir" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Ozlem Nuray" "apellidos" => "Sever" ] 1 => array:2 [ "nombre" => "Umut" "apellidos" => "Elboga" ] 2 => array:2 [ "nombre" => "Ertan" "apellidos" => "Sahin" ] 3 => array:2 [ "nombre" => "Yusuf Burak" "apellidos" => "Cayirli" ] 4 => array:2 [ "nombre" => "Havva" "apellidos" => "Yesil Cinkir" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S2253654X21002031" "doi" => "10.1016/j.remn.2021.11.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253654X21002031?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253808921001737?idApp=UINPBA00004N" "url" => "/22538089/0000004200000002/v2_202311010503/S2253808921001737/v2_202311010503/en/main.assets" ] "en" => array:21 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "PET/CT in nuclear endocrinology: Results of the survey diffused through different social networks of the SEMNIM in Spain" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "77" "paginaFinal" => "82" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "M. Negre Busó, M. Estorch Cabrera, M. Mitjavila Casanovas" "autores" => array:4 [ 0 => array:4 [ "nombre" => "M." "apellidos" => "Negre Busó" "email" => array:1 [ 0 => "montserrat.negre.idi@gencat.cat" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "M." "apellidos" => "Estorch Cabrera" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 2 => array:3 [ "nombre" => "M." "apellidos" => "Mitjavila Casanovas" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] ] ] 3 => array:1 [ "colaborador" => "on behalf of the SEMNIM Endocrinology Working Group" ] ] "afiliaciones" => array:4 [ 0 => array:3 [ "entidad" => "Servicio de Medicina Nuclear-IDI, Hospital Universitari de Girona Dr. Josep Trueta, Girona, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Grupo de Trabajo de Endocrinología de la SEMNIM" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Servicio de Medicina Nuclear, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Servicio de Medicina Nuclear, Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain" "etiqueta" => "d" "identificador" => "aff0020" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "PET/TC en endocrinología nuclear. Resultados de la encuesta difundida por las distintas redes sociales de la SEMNIM en España" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1299 "Ancho" => 1675 "Tamanyo" => 92053 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0055" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Localization of the centers participating in the survey by autonomous community.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Introduction</span><p id="par0155" class="elsevierStylePara elsevierViewall">The Working Group of Endocrinology of the Spanish Society of Nuclear Medicine and Molecular Imaging proposed the need to determine the current use of positron emission tomography/computerized tomography (PET/CT) in the field of endocrinology. The aim of the survey was to obtain a snapshot of the use of PET/CT in nuclear endocrinology with the aim of knowing whether it is being adequately used and detect possible needs at a time when new radiopharmaceuticals are being marketed and their availability is much greater and more extended in our country.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Material and methods</span><p id="par0160" class="elsevierStylePara elsevierViewall">During the first quarter of 2022, the data obtained from a survey distributed through different social networks during the second quarter of 2021 were analyzed. The survey collected data on the availability of PET/CT equipment in Nuclear Medicine Departments, the number of patients diagnosed with differentiated thyroid cancer (DTC), the use and indications of <span class="elsevierStyleSup">18</span>F-FDG PET/CT in DTC, the number of patients diagnosed with medullary thyroid carcinoma (MTC) and the use of f <span class="elsevierStyleSup">18</span>F-DOPA in the diagnosis of biochemical recurrence of MTC, the use of <span class="elsevierStyleSup">18</span>F-DOPA and <span class="elsevierStyleSup">68</span>Ga-DOTA-SA in the study of neuroendocrine tumors (NET) and the indications and the use of <span class="elsevierStyleSup">18</span>F-Choline in the study of hyperparathyroidism (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>).</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Results</span><p id="par0165" class="elsevierStylePara elsevierViewall">Knowledge as to whether studies with PET/CT are being adequately used in endocrinology in Spain could not be optimally analyzed due to the limited number of participating centers. Nonetheless, the results are described below.</p><p id="par0170" class="elsevierStylePara elsevierViewall">A total of 15 centers responded to the survey, representing less than 15% of the Nuclear Medicine centers in Spain (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>). Only two of the participating departments did not have PET/CT equipment.</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Differentiated thryoid cancer</span><p id="par0175" class="elsevierStylePara elsevierViewall">Fourteen hospitals responded to questions related to this subject, with the number of patients diagnosed with DTC being 25–230 per year. In 79% of the hospitals <span class="elsevierStyleSup">18</span>F-FDG PET/CT was used in the diagnosis and follow-up of DTC, with a mean number of 36.9 (range: 10–100) studies per year. The indications in order of frequency were: evaluation of response to therapy with anti-tyrosine-kinase drugs (9/14 hospitals), patients with a negative radioiodine scan and increase in thyroglobulin values (Tg) greater than 10<span class="elsevierStyleHsp" style=""></span>ng/mL (8/14), initial staging in patients with an unfavorable histology (7/14), and patients with a negative radioiodine scan with any increase in Tg values (6/14) (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>). The Hospital Regional Universitario de Málaga (100), Hospital Puerta del Hierro (40) and the Hospital de la Santa Creu i Sant Pau (39) reported the greatest number of studies performed.</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Medullary thyroid cancer</span><p id="par0180" class="elsevierStylePara elsevierViewall">Of the 13 hospitals that responded to questions related to this subject, 85% used <span class="elsevierStyleSup">18</span>F-DOPA PET/CT for the study of biochemical recurrence of MTC, with a range of 3–30 patients diagnosed per year and a mean of 7.8 studies performed annually (range 2–20) (<a class="elsevierStyleCrossRef" href="#fig0015">Fig. 3</a>). The main departments requesting this study were Endocrinology and Oncology and also the Department of Otorhinolaryngology in one hospital. The Hospital Vall d’Hebron (8 patients), the Hospitalario Universitario de Santiago de Compostela (20 patients), Hospital La Fe de Valencia (12 patients) and the Hospital Puerta del Hierro (7 patients) reported the largest number of studies performed.</p><elsevierMultimedia ident="fig0015"></elsevierMultimedia></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Neuroendocrine tumors (gastroenteropancreatic tumors, paragangliomas and pheochromocytomas)</span><p id="par0185" class="elsevierStylePara elsevierViewall">Of the 14 hospitals, 77% used <span class="elsevierStyleSup">18</span>F-DOPA PET/CT for the study of NET, with a mean of 10 studies annually (range 2–30). The indications in the order of frequency were: the study of malignant pheochromocytoma (9/14), the study of malignant paraganglioma (9/14), the study of hyperinsulinism (8/14) and others (3/14) such as ileal NET and the study or suspicion of gastenteropancreatic NET not detected with other techniques (<a class="elsevierStyleCrossRef" href="#fig0020">Fig. 4</a>). The hospitals HUCA Asturias (30 patients), Bellvitge (20 patients), Hospitalario Universitario de Santiago de Compostela (20 patients) and La Fe de Valencia (10 patients) carried out the highest number of studies.</p><elsevierMultimedia ident="fig0020"></elsevierMultimedia><p id="par0190" class="elsevierStylePara elsevierViewall">Among 13 hospitals, 69% used <span class="elsevierStyleSup">68</span>Ga-DOTA-SA for the study of initial staging and suspicion of recurrence of NET, with a mean of 24.7 studies per year (range 2–127). In order of frequency the indications were: the study of gastroenteropancreatic NET for both the staging and suspicion of recurrence (10/13), study of carcinoid tumor (9/13), study of malignant paraganglioma (6/13), evaluation of response to peptide receptor radionuclide therapy (PRRT) (6/13), others (3/13) such as the study of inadequate adrenocorticotropic hormone secretion, the study of focal nodular hyperplasia or the study of meningiomas (<a class="elsevierStyleCrossRef" href="#fig0025">Fig. 5</a>). The Bellvitge (50 patients), Vall d’Hebron (120 patients), and Santa Creu i Sant Pau hospitals (36 patients), and the Hospitalario Universitario de Santiago de Compostela in A Coruña (120 patients), Hospital La Fe de Valencia (127 patients) and the Hospital Clínico Universitario Virgen de la Arrixaca (60 patients) reported performing the greatest number of studies.</p><elsevierMultimedia ident="fig0025"></elsevierMultimedia></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Hyperparathyroidism</span><p id="par0195" class="elsevierStylePara elsevierViewall">Seventy nine percent of the 14 hospitals used <span class="elsevierStyleSup">18</span>F-Choline PET/CT for the study of hyperparathyroidism, reporting a mean of 30.1 studies per year (range 10–20), with some studies noting in the comments that the technique most commonly used was <span class="elsevierStyleSup">99m</span>Tc-SESTAMIBI.</p></span></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Discussion</span><p id="par0200" class="elsevierStylePara elsevierViewall">The low prevalence of most of these endocrine diseases makes multicenter participation in this type of survey essential to know our strengths and weaknesses and improve what is being carried out in daily clinical practice. The results show that there is great heterogeneity in the use of PET/CT in nuclear endocrinology in Spain. Not all the centers have their own PET/CT equipment and the most complex endocrine diseases such as DTC, MTC and NET are centralized in hospitals with a larger patient volume and greater experience and expertise. The lack of guidelines with clear indications of the use of PET/CT in nuclear endocrinology also hinders the implementation of these studies.</p><p id="par0205" class="elsevierStylePara elsevierViewall">Evidence of the utility of <span class="elsevierStyleSup">18</span>F-FDG PET/CT in the study of DTC is extensive,<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1–4</span></a> and despite this, not all the centers usually use this study. The most frequent indication is the evaluation of response to therapy with anti-tyrosine-kinase therapy, followed by the evaluation of patients with a negative radioiodine scan and Tg greater than 10<span class="elsevierStyleHsp" style=""></span>ng/mL. Interestingly, due to the lack of approved criteria of response with FDG, the RECIST criteria, which are not validated for this type of disease, continue to be used. In addition, since the relationship between the incorporation of FDG and radioiodine does not seem to be a simple flip-flop phenomenon but rather the mutational profile and several molecular may play a main role in their incorporation, some articles and the consensus documents of the American Neurological Association, European Thyroid Association, Society of Nuclear Medicine and European Association of Nuclear Medicine<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a> state that the integration of FDG PET/CT with radioiodine studies may provide important information in the theragnostic model of stratification of risk in unfavorable or more aggressive histologies.</p><p id="par0210" class="elsevierStylePara elsevierViewall">On the other hand, it is essential to take into account not only the Tg value but also the doubling time of this value and the evolution of anti-Tg antibodies: progressive increase or conversion of negative to positive values.<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2–4</span></a></p><p id="par0215" class="elsevierStylePara elsevierViewall">In the case of PET/CT in the study of MTC, more than 80% of the centers use this technique, although according to the number of patients reported, its use seems to still be quite anecdotic and with great variability among centers. It has been shown that <span class="elsevierStyleSup">18</span>F-DOPA presents a very good sensitivity for the detection of lesions. However, the low incidence of the disease and the current indications, which basically restrict this technique to patients with suspicion of disease persistence or relapse if calcitonin values are greater than 150<span class="elsevierStyleHsp" style=""></span>pg/mL,<a class="elsevierStyleCrossRefs" href="#bib0025"><span class="elsevierStyleSup">5–7</span></a> are factors that condition the low number of studies and only hospitals with a large volume of patients perform the most significant number of studies. <span class="elsevierStyleSup">18</span>F-FDG also has a role in the study of MTC in the case of aggressive disease with calcitonin values greater than 500<span class="elsevierStyleHsp" style=""></span>pg/mL, although this was not included in the survey.</p><p id="par0220" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleSup">68</span>Ga-DOTA-SA is the radiopharmaceutical of choice in patients diagnosed with or suspected of having well differentiated NET. It has demonstrated to have the greatest sensitivity for the localization of the primary tumor and its extension.<a class="elsevierStyleCrossRefs" href="#bib0040"><span class="elsevierStyleSup">8,9</span></a> However, in the survey it was the technique with the lowest percentage of use (69%). Some of the reasons for this may be the generalized lack of availability throughout the country, its physical characteristics (which impede its implementation in sites far from the production center) and the cost. In the last years different consensus on the use of PET/CT in NET and paragangliomas/pheochromocytomas<a class="elsevierStyleCrossRefs" href="#bib0050"><span class="elsevierStyleSup">10,11</span></a> have been published and recommend the use of <span class="elsevierStyleSup">68</span>Ga-DOTA-SA (associated with diagnostic CT) for diagnosis, including the detection of the primary unknown tumor, for staging, for restaging following surgery, in cases of suspicion or diagnosis of progression and for the selection of PRRT. On the other hand, the use of <span class="elsevierStyleSup">18</span>F-FDG is recommended in NET G3, in neuroendocrine carcinoma, cases with morphological lesions in the CT without uptake of <span class="elsevierStyleSup">68</span>Ga-DOTA-SA and in cases presenting rapid progression independently of tumoral grade. The use of <span class="elsevierStyleSup">68</span>Ga-DOTA-SA is also recommended in paragangliomas when extra suprarenal localization is suspected, with or without lesions by CT. According to the survey performed, these indications do not differ from those most commonly used in Spain.</p><p id="par0225" class="elsevierStylePara elsevierViewall">The role of <span class="elsevierStyleSup">18</span>F-DOPA in the study of NET is not as well defined. Its mechanism of incorporation is not receptor-based but is based on the transport of amino acids L, and the choice of the optimal radiopharmaceutical should be guided by the location of the tumor and genetic alterations (if available). <span class="elsevierStyleSup">18</span>F-DOPA is useful in NET with high amino acid metabolism and with low expression of somatostatin receptors, such as in paragangliomas (with RET, NF1, MAX, VHL mutations), NET of the small intestine and the study of endogenous hyperinsulinism, especially for differentiating between focal or diffuse involvement in children.<a class="elsevierStyleCrossRefs" href="#bib0060"><span class="elsevierStyleSup">12,13</span></a></p><p id="par0230" class="elsevierStylePara elsevierViewall">The results of the survey indicate that similar to what occurs in MTC, the use of <span class="elsevierStyleSup">18</span>F-DOPA in the study of pheochromocytoma/paraganglioma type NET and hyperinsulinism is infrequent and mainly restricted to hospitals with a larger reference population.</p><p id="par0235" class="elsevierStylePara elsevierViewall">The use of <span class="elsevierStyleSup">18</span>F-Choline PET/CT for the study of hyperparathyroidism is increasingly more extended and many publications endorse its use.<a class="elsevierStyleCrossRefs" href="#bib0070"><span class="elsevierStyleSup">14–17</span></a> However, the lack of inclusion of this indication in the product specification sheet and the need to obtain informed consent for the use of mediations already authorized in conditions other than those established hinder its routine use. The survey only asked about its use in general and did not focus on knowing its most frequent indications, making this an important limitation. It cannot be forgotten that <span class="elsevierStyleSup">99m</span>Tc-SESTAMIBI studies carried out with an optimal protocol can provide very good results and that the use of choline-PET should be reserved for patients with surgical indication and with a previous negative optimal methoxyisobutyl isonitrile study.</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Limitations</span><p id="par0240" class="elsevierStylePara elsevierViewall">The main limitation of the study is that the sample was little representative due to the low participation of the different Nuclear Medicine Departments, making extrapolation of the results to generalized use of the technique in Spain impossible. Nonetheless, the data obtained allow continued work in the implementation of the PET technique in Spain.</p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Conclusions</span><p id="par0245" class="elsevierStylePara elsevierViewall">The use of the PET/CT technique in endocrinology is not yet generalized. However, the data obtained from the survey performed show that the indications for which it is used are, in general, those described in the different consensus documents. Economic factors, the distribution of the population and the general low prevalence of some endocrinological diseases allow hospitals located in large cities and with large reference populations to have greater availability of resources and, thus, a larger study volume.</p><p id="par0250" class="elsevierStylePara elsevierViewall">Here lies the importance of the participation of centers in surveys of this type. It is necessary to join efforts in little prevalent diseases, establishing mechanisms of interhospitalary collaboration, which, albeit difficult, could provide very valuable information on the real use of the PET/CT technique, if used correctly, to detect the problems of technique accessibility and points for improvement.</p></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Funding</span><p id="par0255" class="elsevierStylePara elsevierViewall">This study did not receive any funding from the public or commercial sector or from non-profit organizations.</p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Conflict of interests</span><p id="par0260" class="elsevierStylePara elsevierViewall">The authors declare they have no conflict of interest.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:14 [ 0 => array:3 [ "identificador" => "xres2001073" "titulo" => "Abstract" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Aim" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Material and methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1715023" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres2001072" "titulo" => "Resumen" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Objetivo" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Material y métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusiones" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec1715024" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:2 [ "identificador" => "sec0010" "titulo" => "Material and methods" ] 6 => array:3 [ "identificador" => "sec0015" "titulo" => "Results" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "sec0020" "titulo" => "Differentiated thryoid cancer" ] 1 => array:2 [ "identificador" => "sec0025" "titulo" => "Medullary thyroid cancer" ] 2 => array:2 [ "identificador" => "sec0030" "titulo" => "Neuroendocrine tumors (gastroenteropancreatic tumors, paragangliomas and pheochromocytomas)" ] 3 => array:2 [ "identificador" => "sec0035" "titulo" => "Hyperparathyroidism" ] ] ] 7 => array:2 [ "identificador" => "sec0040" "titulo" => "Discussion" ] 8 => array:2 [ "identificador" => "sec0045" "titulo" => "Limitations" ] 9 => array:2 [ "identificador" => "sec0050" "titulo" => "Conclusions" ] 10 => array:2 [ "identificador" => "sec0055" "titulo" => "Funding" ] 11 => array:2 [ "identificador" => "sec0060" "titulo" => "Conflict of interests" ] 12 => array:2 [ "identificador" => "xack699238" "titulo" => "Acknowledgments" ] 13 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2022-08-17" "fechaAceptado" => "2022-09-14" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1715023" "palabras" => array:3 [ 0 => "Survey" 1 => "PET/CT" 2 => "Endocrinology" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec1715024" "palabras" => array:3 [ 0 => "Encuesta" 1 => "PET/TC" 2 => "Endocrinología" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:3 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Aim</span><p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">To know the current use of the PET/CT technology applied in the field of endocrinology, the Endocrinology Working Group of SEMNIM proposed conducting a survey. The objective was to obtain a snapshot of the use of PET/CT in nuclear endocrinology, to know if it is being used properly and detect possible needs.</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Material and methods</span><p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">During the first quarter of 2022, we analyzed the data obtained from a survey that was distributed through different social networks throughout the second half of 2021. The survey asked for the use of the different PET/CT techniques available in Spain in different endocrinological pathologies like differentiated thyroid carcinoma, medullary thyroid carcinoma, neuroendocrine tumors and hyperparathyroidism.</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Results</span><p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">A total of 15 centers responded to the survey. A percentage of 79 of hospitals used <span class="elsevierStyleSup">18</span>F-FDG PET/CT in the diagnosis and/or follow-up of differentiated thyroid carcinoma (mean annual studies: 36.9; range 10–100); 85% used <span class="elsevierStyleSup">18</span>F-DOPA PET/CT for the study of biochemical recurrence of medullary thyroid carcinoma (mean annual studies: 7.8; range 2–20); 77% used <span class="elsevierStyleSup">18</span>F-DOPA PET/CT for the study of neuroendocrine tumors: 77% used <span class="elsevierStyleSup">18</span>F-DOPA PET/CT (mean of 10 scans per year; range 2–30) and 69% used 68Ga-DOTA-SA (mean of 24.7 studies per year; range 2–127); 79% used <span class="elsevierStyleSup">18</span>F-choline PET/CT for the study of hyperparathyroidism (mean of 30.1 annual studies; range 10–120).</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Conclusions</span><p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">We detected that the use of the PET/CT technique in endocrinology is not yet widespread, however, we saw that the indications in which it is used are, in general, those reported in the different consensus.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Aim" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Material and methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] "es" => array:3 [ "titulo" => "Resumen" "resumen" => "<span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Objetivo</span><p id="spar0090" class="elsevierStyleSimplePara elsevierViewall">Desde el Grupo de Trabajo de Endocrinología de la SEMNIM, se planteó la necesidad de conocer el uso actual de la tecnología PET/TC aplicada en el campo de la endocrinología. El objetivo de la encuesta era obtener una fotografía instantánea del uso de la PET/TC en endocrinología nuclear, con el fin de conocer si está siendo adecuadamente utilizada y detectar posibles necesidades.</p></span> <span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Material y métodos</span><p id="spar0095" class="elsevierStyleSimplePara elsevierViewall">Durante el primer trimestre del 2022, se analizaron los datos obtenidos de una encuesta que se difundió a través de distintas redes sociales a lo largo de la segunda mitad del 2021. Se recogieron datos sobre el uso de las distintas técnicas PET/TC en el carcinoma diferenciado de tiroides, el carcinoma medular de tiroides, los tumores neuroendocrinos y el hiperparatiroidismo.</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Resultados</span><p id="spar0100" class="elsevierStyleSimplePara elsevierViewall">Un total de 15 centros respondieron la encuesta. El 79% de los hospitales utilizan la <span class="elsevierStyleSup">18</span>F-FDG PET/TC en el diagnóstico y/o seguimiento del carcinoma diferenciado de tiroides (media de exploraciones anuales: 36,9; rango 10–100). El 85% utilizan la <span class="elsevierStyleSup">18</span>F-DOPA PET/TC para el estudio de recidiva bioquímica de carcinoma medular de tiroides (media estudios anuales: 7,8; rango 2–20). El 77% utilizan la <span class="elsevierStyleSup">18</span>F-DOPA PET/TC para el estudio de los tumores neuroendocrinos: el 77% utilizan la <span class="elsevierStyleSup">18</span>F-DOPA PET/TC (media de 10 exploraciones anuales; rango 2–30) y el 69% utilizan el 68Ga-DOTA-SA (media de 24,7 exploraciones anuales; rango 2–127). El 79% utilizan la <span class="elsevierStyleSup">18</span>F-colina PET/TC para el estudio del hiperparatiroidismo (media de 30,1 exploraciones anuales; rango 10–120).</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Conclusiones</span><p id="spar0105" class="elsevierStyleSimplePara elsevierViewall">El uso de la técnica PET/TC en endocrinología aún no está generalizado, sin embargo, vimos que las indicaciones en las cuales se utiliza son, en general, las reportadas en los distintos consensos.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Objetivo" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Material y métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusiones" ] ] ] ] "apendice" => array:1 [ 0 => array:1 [ "seccion" => array:1 [ 0 => array:4 [ "apendice" => "<p id="par0345" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0045"><li class="elsevierStyleListItem" id="lsti0155"><span class="elsevierStyleLabel">•</span><p id="par0270" class="elsevierStylePara elsevierViewall">Complejo Hospitalario Universitario de Santiago de Compostela (A Coruña)</p></li><li class="elsevierStyleListItem" id="lsti0160"><span class="elsevierStyleLabel">•</span><p id="par0275" class="elsevierStylePara elsevierViewall">Hospital Universitario Parc Taulí (Barcelona)</p></li><li class="elsevierStyleListItem" id="lsti0165"><span class="elsevierStyleLabel">•</span><p id="par0280" class="elsevierStylePara elsevierViewall">Gammacámara Murcia SL (Múrcia)</p></li><li class="elsevierStyleListItem" id="lsti0170"><span class="elsevierStyleLabel">•</span><p id="par0285" class="elsevierStylePara elsevierViewall">Complejo Hospitalario Navarra (Navarra)</p></li><li class="elsevierStyleListItem" id="lsti0175"><span class="elsevierStyleLabel">•</span><p id="par0290" class="elsevierStylePara elsevierViewall">Hospital Regional Universitario de Málaga (Málaga)</p></li><li class="elsevierStyleListItem" id="lsti0180"><span class="elsevierStyleLabel">•</span><p id="par0295" class="elsevierStylePara elsevierViewall">Hospital Clínico Universitario Virgen de la Arrixaca (Múrcia)</p></li><li class="elsevierStyleListItem" id="lsti0185"><span class="elsevierStyleLabel">•</span><p id="par0300" class="elsevierStylePara elsevierViewall">Hospital Universitario Getafe (Madrid).</p></li><li class="elsevierStyleListItem" id="lsti0190"><span class="elsevierStyleLabel">•</span><p id="par0305" class="elsevierStylePara elsevierViewall">Hospital Puerta de Hierro Majadahonda (Madrid)</p></li><li class="elsevierStyleListItem" id="lsti0195"><span class="elsevierStyleLabel">•</span><p id="par0310" class="elsevierStylePara elsevierViewall">Hospital de la Santa Creu i Sant Pau (Barcelona)</p></li><li class="elsevierStyleListItem" id="lsti0200"><span class="elsevierStyleLabel">•</span><p id="par0315" class="elsevierStylePara elsevierViewall">Hospital Universitari de Bellvitge (Barcelona)</p></li><li class="elsevierStyleListItem" id="lsti0205"><span class="elsevierStyleLabel">•</span><p id="par0320" class="elsevierStylePara elsevierViewall">HUCA Asturias (Asturias)</p></li><li class="elsevierStyleListItem" id="lsti0210"><span class="elsevierStyleLabel">•</span><p id="par0325" class="elsevierStylePara elsevierViewall">Hospital Vall d'Hebron (Barcelona)</p></li><li class="elsevierStyleListItem" id="lsti0215"><span class="elsevierStyleLabel">•</span><p id="par0330" class="elsevierStylePara elsevierViewall">H. U. P. La Fe (Valencia)</p></li><li class="elsevierStyleListItem" id="lsti0220"><span class="elsevierStyleLabel">•</span><p id="par0335" class="elsevierStylePara elsevierViewall">Hospital Universitario Virgen Macarena (Sevilla)</p></li><li class="elsevierStyleListItem" id="lsti0225"><span class="elsevierStyleLabel">•</span><p id="par0340" class="elsevierStylePara elsevierViewall">Hospital Universitario de Girona Dr. Josep Trueta (Girona)</p></li></ul></p>" "etiqueta" => "Appendix A" "titulo" => "Centers that participated in the national survey on the use of PET/CT in nuclear endocrinology" "identificador" => "sec0065" ] ] ] ] "multimedia" => array:6 [ 0 => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1299 "Ancho" => 1675 "Tamanyo" => 92053 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0055" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Localization of the centers participating in the survey by autonomous community.</p>" ] ] 1 => array:8 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1902 "Ancho" => 2091 "Tamanyo" => 183501 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0060" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Use of <span class="elsevierStyleSup">18</span>F-FDG PET/CT in the diagnosis and/or follow-up of differentiated thyroid cancer.</p> <p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">A. Number of centers that use the technique compared to the total (percentage).</p> <p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">B. Relationship of the number of centers that use the technique in the indication described.</p>" ] ] 2 => array:8 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 1014 "Ancho" => 1675 "Tamanyo" => 60712 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0065" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Use of <span class="elsevierStyleSup">18</span>F-DOPA in the study of recurrence of medullary thyroid cancer.</p> <p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Number of centers that use the technique compared to the total (percentage).</p>" ] ] 3 => array:8 [ "identificador" => "fig0020" "etiqueta" => "Figure 4" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr4.jpeg" "Alto" => 2422 "Ancho" => 2091 "Tamanyo" => 184185 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0070" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Use of <span class="elsevierStyleSup">18</span>F-DOPA in the study of neuroendocrine tumors.</p> <p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">A. Number of centers that use the technique compared to the total (percentage).</p> <p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">B. Relationship of the number of centers that use the technique in the indication described.</p>" ] ] 4 => array:8 [ "identificador" => "fig0025" "etiqueta" => "Figure 5" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr5.jpeg" "Alto" => 2248 "Ancho" => 2091 "Tamanyo" => 196015 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0075" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Use of <span class="elsevierStyleSup">68</span>Ga-DOTA-SA in the study of neuroendocrine tumors.</p> <p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">A. Number of centers that use the technique compared to the total (percentage).</p> <p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">B. Relationship of the number of centers that use the technique in the indication described.</p>" ] ] 5 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0080" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">General question</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">-</span><p id="par0005" class="elsevierStylePara elsevierViewall">Does your Nuclear Medicine Department have PET/CT equipment?</p></li></ul> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleBold">Specific questions</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Differentiated thyroid cancer<ul class="elsevierStyleList" id="lis0010"><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">-</span><p id="par0010" class="elsevierStylePara elsevierViewall">How many patients are diagnosed with DTC per year?</p></li><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">-</span><p id="par0015" class="elsevierStylePara elsevierViewall">Do you use <span class="elsevierStyleSup">18</span>F-FDG in the diagnosis and/or follow-up of DTC?</p></li><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">-</span><p id="par0020" class="elsevierStylePara elsevierViewall">If yes, how many studies do you perform per year?</p></li><li class="elsevierStyleListItem" id="lsti0025"><span class="elsevierStyleLabel">-</span><p id="par0025" class="elsevierStylePara elsevierViewall">Mark with a cross the indications for <span class="elsevierStyleSup">18</span>F-FDG studies:<ul class="elsevierStyleList" id="lis0015"><li class="elsevierStyleListItem" id="lsti0030"><span class="elsevierStyleLabel">o</span><p id="par0030" class="elsevierStylePara elsevierViewall">Scan with negative radioiodine and increase of Tg (any value).</p></li><li class="elsevierStyleListItem" id="lsti0035"><span class="elsevierStyleLabel">o</span><p id="par0035" class="elsevierStylePara elsevierViewall">Negative radioiodine scan and increase of Tg (value<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>10).</p></li><li class="elsevierStyleListItem" id="lsti0040"><span class="elsevierStyleLabel">o</span><p id="par0040" class="elsevierStylePara elsevierViewall">Initial staging in patients with unfavorable histology (poorly differentiated/undifferentiated).</p></li><li class="elsevierStyleListItem" id="lsti0045"><span class="elsevierStyleLabel">o</span><p id="par0045" class="elsevierStylePara elsevierViewall">Response to anti-TK therapy.</p></li></ul></p></li></ul> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Medullary thyroid cancer<ul class="elsevierStyleList" id="lis0020"><li class="elsevierStyleListItem" id="lsti0050"><span class="elsevierStyleLabel">-</span><p id="par0050" class="elsevierStylePara elsevierViewall">How many patients are diagnosed with MTC per year?</p></li><li class="elsevierStyleListItem" id="lsti0055"><span class="elsevierStyleLabel">-</span><p id="par0055" class="elsevierStylePara elsevierViewall">Do you use <span class="elsevierStyleSup">18</span>F-DOPA in the study of recurrence of MTC?</p></li><li class="elsevierStyleListItem" id="lsti0060"><span class="elsevierStyleLabel">-</span><p id="par0060" class="elsevierStylePara elsevierViewall">If yes, how many studies do you perform per year?</p></li><li class="elsevierStyleListItem" id="lsti0065"><span class="elsevierStyleLabel">-</span><p id="par0065" class="elsevierStylePara elsevierViewall">What are the main departments requesting studies with <span class="elsevierStyleSup">18</span>F-DOPA for MTC?</p></li></ul> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Hyperparathyroidism<ul class="elsevierStyleList" id="lis0025"><li class="elsevierStyleListItem" id="lsti0070"><span class="elsevierStyleLabel">-</span><p id="par0070" class="elsevierStylePara elsevierViewall">Do you use <span class="elsevierStyleSup">18</span>F-Choline in the study of hyperparathyroidism?</p></li><li class="elsevierStyleListItem" id="lsti0075"><span class="elsevierStyleLabel">-</span><p id="par0075" class="elsevierStylePara elsevierViewall">If yes, how many studies do you perform per year?</p></li></ul> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Neuroendocrine tumors:<ul class="elsevierStyleList" id="lis0030"><li class="elsevierStyleListItem" id="lsti0080"><span class="elsevierStyleLabel">-</span><p id="par0080" class="elsevierStylePara elsevierViewall">Do you use <span class="elsevierStyleSup">18</span>F-DOPA in the study of NET?</p></li><li class="elsevierStyleListItem" id="lsti0085"><span class="elsevierStyleLabel">-</span><p id="par0085" class="elsevierStylePara elsevierViewall">If yes, how many studies do you perform per year?</p></li><li class="elsevierStyleListItem" id="lsti0090"><span class="elsevierStyleLabel">-</span><p id="par0090" class="elsevierStylePara elsevierViewall">Mark with a cross the indications for studies with <span class="elsevierStyleSup">18</span>F-DOPA:<ul class="elsevierStyleList" id="lis0035"><li class="elsevierStyleListItem" id="lsti0095"><span class="elsevierStyleLabel">o</span><p id="par0095" class="elsevierStylePara elsevierViewall">Study of malignant pheochromocytoma.</p></li><li class="elsevierStyleListItem" id="lsti0100"><span class="elsevierStyleLabel">o</span><p id="par0100" class="elsevierStylePara elsevierViewall">Study of malignant paraganglioma.</p></li><li class="elsevierStyleListItem" id="lsti0105"><span class="elsevierStyleLabel">o</span><p id="par0105" class="elsevierStylePara elsevierViewall">Study of hyperinsulinism</p></li><li class="elsevierStyleListItem" id="lsti0110"><span class="elsevierStyleLabel">o</span><p id="par0110" class="elsevierStylePara elsevierViewall">Others (please state)</p></li></ul></p></li><li class="elsevierStyleListItem" id="lsti0115"><span class="elsevierStyleLabel">-</span><p id="par0115" class="elsevierStylePara elsevierViewall">¿Do you use <span class="elsevierStyleSup">68</span>Ga-SA in the study of NET?</p></li><li class="elsevierStyleListItem" id="lsti0120"><span class="elsevierStyleLabel">-</span><p id="par0120" class="elsevierStylePara elsevierViewall">If yes, how many studies do you perform per year?</p></li><li class="elsevierStyleListItem" id="lsti0125"><span class="elsevierStyleLabel">-</span><p id="par0125" class="elsevierStylePara elsevierViewall">Mark with a cross the indications for studies with <span class="elsevierStyleSup">167</span>Ga-SA:<ul class="elsevierStyleList" id="lis0040"><li class="elsevierStyleListItem" id="lsti0130"><span class="elsevierStyleLabel">o</span><p id="par0130" class="elsevierStylePara elsevierViewall">Study of gastroenteropancreatic NET (staging, suspicion of recurrence)</p></li><li class="elsevierStyleListItem" id="lsti0135"><span class="elsevierStyleLabel">o</span><p id="par0135" class="elsevierStylePara elsevierViewall">Study of carcinoid tumor</p></li><li class="elsevierStyleListItem" id="lsti0140"><span class="elsevierStyleLabel">o</span><p id="par0140" class="elsevierStylePara elsevierViewall">Study of malignant paraganglioma</p></li><li class="elsevierStyleListItem" id="lsti0145"><span class="elsevierStyleLabel">o</span><p id="par0145" class="elsevierStylePara elsevierViewall">Evaluation of response to PRRT</p></li><li class="elsevierStyleListItem" id="lsti0150"><span class="elsevierStyleLabel">o</span><p id="par0150" class="elsevierStylePara elsevierViewall">Others (please state)</p></li></ul></p></li></ul> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab3323201.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Questions included in the survey sent through different social networks.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:17 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Diagnostic performance of 18F-FDG-PET/CT in DTC patients with thyroglobuline elevation and negative iodine scintigraphy: a meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "W. Qichang" 1 => "B. Lin" 2 => "Z. Gege" 3 => "Y. Zhan" 4 => "M. Qingjie" 5 => "W. Renjie" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1530/EJE-19-0261" "Revista" => array:6 [ "tituloSerie" => "Eur J Endocrinol" "fecha" => "2019" "volumen" => "181" "paginaInicial" => "93" "paginaFinal" => "102" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31117054" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "PET/CT in the management of differentiatied thyroid cancer. Diagnostic and interventional imaging" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "E. Zampella" 1 => "M. Klain" 2 => "L. Pace" 3 => "A. Cuocolo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.diii.2021.04.004" "Revista" => array:7 [ "tituloSerie" => "Diagn Interv Imaging" "fecha" => "2021" "volumen" => "102" "paginaInicial" => "515" "paginaFinal" => "523" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33926848" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1474442220301824" "estado" => "S300" "issn" => "14744422" ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid association, the Society of Nuclear Medicine and Molecular Imaging on Current Diagnostic and theranostic approaches in the management of Thyroid Cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.A. Gulec" 1 => "S. Ahuja" 2 => "A.M. Avram" 3 => "V. Bernet" 4 => "P. Bourguet" 5 => "C. Draganescu" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1089/thy.2020.0826" "Revista" => array:7 [ "tituloSerie" => "Thyroid" "fecha" => "2021" "volumen" => "31" "paginaInicial" => "1009" "paginaFinal" => "1019" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33789450" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S147444221730371X" "estado" => "S300" "issn" => "14744422" ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Utilidad de la 18F-FDG PET/TC en el cáncer de tiroides" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "M.A. Muros" 1 => "M. Mitjavila" 2 => "M. Estorch" 3 => "B. Lecumberri" 4 => "E. Navarro" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.remn.2016.01.006" "Revista" => array:6 [ "tituloSerie" => "Rev Esp Med Nucl Imagen Mol" "fecha" => "2016" "volumen" => "35" "paginaInicial" => "186" "paginaFinal" => "192" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26944558" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Which is the optimal scan time of 18F-DOPA PET/CT in patients with recurrent Medullary Thyroid Carcinoma? Results from a dynamic acquisition study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "S. Taralli" 1 => "M. Lorusso" 2 => "A. Capotosti" 3 => "V. Lanni" 4 => "L. Indovina" 5 => "V. Rufini" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/RLU.0000000000002925" "Revista" => array:6 [ "tituloSerie" => "Clin Nucl Med" "fecha" => "2020" "volumen" => "45" "paginaInicial" => "e134" "paginaFinal" => "e140" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31977485" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Imaging medullary thyroid cancer patients with detectable serum markers: state of the art and future perspectives" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "M. Klain" 1 => "J. Hadoux" 2 => "C. Nappi" 3 => "M. Finessi" 4 => "R. Ambrosio" 5 => "M. Schlumberger" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s12020-021-02930-8" "Revista" => array:7 [ "tituloSerie" => "Endocrine" "fecha" => "2022" "volumen" => "75" "paginaInicial" => "330" "paginaFinal" => "337" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34748168" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1470204512702115" "estado" => "S300" "issn" => "14702045" ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Functional imaging in thyroid cancer patients with metastases and therapeutic implications" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "M. Schlumberger" 1 => "C. Garcia" 2 => "J. Hadoux" 3 => "M. Klain" 4 => "L. Lamartina" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "Presse Med" "fecha" => "2022" "volumen" => "51" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The impact of somatostatine receptor-directed PET/CT on the management of patients with neuroendocrine tumor: a systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Barrio" 1 => "J. Czernin" 2 => "S. Fanti" 3 => "V. Ambrosini" 4 => "I. Binse" 5 => "L. Du" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2967/jnumed.116.185587" "Revista" => array:6 [ "tituloSerie" => "J Nucl Med" "fecha" => "2017" "volumen" => "58" "paginaInicial" => "756" "paginaFinal" => "761" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28082438" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Anatomic and functional imaging of neuroendocrine tumors" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "B. Morse" 1 => "T. Al-Toubah" 2 => "J. Montilla-Soler" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Curr Treat Options Oncol" "fecha" => "2020" "volumen" => "21" "paginaInicial" => "75" ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T.A. Hope" 1 => "E.K. Bergsland" 2 => "M.F. Bozkurt" 3 => "M. Graham" 4 => "A.P. Heaney" 5 => "K. Herrmann" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2967/jnumed.117.202275" "Revista" => array:6 [ "tituloSerie" => "J Nucl Med" "fecha" => "2018" "volumen" => "59" "paginaInicial" => "66" "paginaFinal" => "74" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29025982" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Consensus on molecular imaging and theranostics in neuroendocrine neoplasms" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "V. Ambronsini" 1 => "J. Kunikowska" 2 => "E. Baudin" 3 => "L. Bodei" 4 => "C. Bouvier" 5 => "J. Capdevila" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ejca.2021.01.008" "Revista" => array:7 [ "tituloSerie" => "Eur J Cancer" "fecha" => "2021" "volumen" => "146" "paginaInicial" => "56" "paginaFinal" => "73" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33588146" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1878875017308550" "estado" => "S300" "issn" => "18788750" ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Novel PET tracers: added value for endocrine disorders" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "S. Bergeret" 1 => "J. Charbit" 2 => "C. Ansquer" 3 => "G. Bera" 4 => "P. Chanson" 5 => "C. Lussey-Lepoutre" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s12020-019-01895-z" "Revista" => array:7 [ "tituloSerie" => "Endocrine" "fecha" => "2019" "volumen" => "64" "paginaInicial" => "14" "paginaFinal" => "30" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30875057" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1474442221001381" "estado" => "S300" "issn" => "14744422" ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Molecular imaging of endocrine neoplasms with emphasis on 18F-DOPA PET: a practical approach for well-tailored imaging protocols" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "C. Fargette" 1 => "A. Imperiale" 2 => "D. Taïed" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.23736/S1824-4785.22.03450-1" "Revista" => array:7 [ "tituloSerie" => "Q J Nucl Med Mol Imaging" "fecha" => "2022" "volumen" => "66" "paginaInicial" => "141" "paginaFinal" => "147" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35343670" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1474442219302327" "estado" => "S300" "issn" => "14744422" ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Identification of occult adenomas in primary hyperparathyroidism with 18F fluorocholine PET/CT" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E. Ballester" 1 => "J.I. Perez" 2 => "D.A. Lopez" 3 => "C. Galan" 4 => "E. Pareja" 5 => "M. Clos" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Cr Esp" "fecha" => "2020" "volumen" => "98" "paginaInicial" => "395" "paginaFinal" => "402" "itemHostRev" => array:3 [ "pii" => "S014067361560160X" "estado" => "S300" "issn" => "01406736" ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "18 fluorocholine PET/CT in the assessment of primary hyperparathyroidism compared with 99mTc-MIBI or 99mTc-tetrofosmin SPECT/CT: a prospective dual-centre study in 100 patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Behesti" 1 => "L. Hehenwarter" 2 => "Z. Paymani" 3 => "G. Rendl" 4 => "L. Imamovic" 5 => "R. Rettenbacher" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00259-018-3980-9" "Revista" => array:7 [ "tituloSerie" => "Eur J Nucl Med Mol Imaging" "fecha" => "2018" "volumen" => "45" "paginaInicial" => "1762" "paginaFinal" => "1771" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29516131" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0140673610604461" "estado" => "S300" "issn" => "01406736" ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "PET/TC 4D 18F-colina en el hiperparatiroidismo: correlación entre datos bioquímicos y parámetros del estudio" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "L.A. Boccalatte" 1 => "N.L. Gómez" 2 => "M. Musumeci" 3 => "A.M. Galich" 4 => "C. Collaud" 5 => "M.F. Figari" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Rev Esp Med Nucl Imagen Mol" "fecha" => "2020" "volumen" => "39" "numero" => "5" "paginaInicial" => "273" "paginaFinal" => "278" ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The EANM practice guidelines for parathyroid imaging" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P.P. Ovcaricek" 1 => "L. Giovanella" 2 => "I. Carrió" 3 => "E. Hindié" 4 => "M.W. Huellner" 5 => "M. Luster" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00259-021-05334-y" "Revista" => array:7 [ "tituloSerie" => "Eur J Nucl Med Mol Imaging" "fecha" => "2021" "volumen" => "48" "paginaInicial" => "2801" "paginaFinal" => "2822" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33839893" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0140673606686546" "estado" => "S300" "issn" => "01406736" ] ] ] ] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:4 [ "identificador" => "xack699238" "titulo" => "Acknowledgments" "texto" => "<p id="par0265" class="elsevierStylePara elsevierViewall">We thank of the professionals from the different Nuclear Medicine Departments who responded to the survey despite their daily work load and the effort involved.</p>" "vista" => "all" ] ] ] "idiomaDefecto" => "en" "url" => "/22538089/0000004200000002/v2_202311010503/S2253808922001094/v2_202311010503/en/main.assets" "Apartado" => array:4 [ "identificador" => "7926" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Original articles" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/22538089/0000004200000002/v2_202311010503/S2253808922001094/v2_202311010503/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253808922001094?idApp=UINPBA00004N" ]
Journal Information
Share
Download PDF
More article options
Original Article
PET/CT in nuclear endocrinology: Results of the survey diffused through different social networks of the SEMNIM in Spain
PET/TC en endocrinología nuclear. Resultados de la encuesta difundida por las distintas redes sociales de la SEMNIM en España
M. Negre Busóa,b,
, M. Estorch Cabrerab,c, M. Mitjavila Casanovasb,d, on behalf of the SEMNIM Endocrinology Working Group
Corresponding author
a Servicio de Medicina Nuclear-IDI, Hospital Universitari de Girona Dr. Josep Trueta, Girona, Spain
b Grupo de Trabajo de Endocrinología de la SEMNIM
c Servicio de Medicina Nuclear, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
d Servicio de Medicina Nuclear, Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain